Preview

July 2019

In the next issue of Pharma Technology Focus, we take a look at the arguments for and against a national drug company in the UK after it was suggested that only a state-run drug company could be trusted to deliver timely results in the fight against superbugs, and dive into a potential treasure trove for drug manufacturers as we examine the rich bacteria source found in underwater forests.


Also, we take a look at the race to get the first nonalcoholic steatohepatitis drug approved for market as industry heavyweights such as Gilead Sciences, Pfizer and Novartis vie to take the lead and explore the therapeutic benefits, risks and market potential of Brexanolone, the world’s first treatment indicated for post-partum depression.


Plus, we find out about Innoplexus AG, an AI company in Frankfurt, which claims to be able to predict trial failures using an algorithm to analyse pharma companies’ drug pipelines, and examine the potential of discovery proteomics, a new innovation in clinical trials being introduced by Swiss pharma giant Roche and proteomics specialist Biognosys.

EDITORIAL

Editor | Eloise McLennan

Group Editor | Susanne Hauner

Commissioning Editor | Daniel Garrun

Writers | Allie Nawrat, Abi Millar
Magazine Designer | Marzia Del Gaone

Graphic Designers | Kate Cuntapay, Anett Arc, Sara Basto, Ashley McPherson, Tyrrell Lowe, Noemi Balint
Lead Designer | John Hammond 
Digital Publishing Director | Duncan West

Advertising

Sales Manager | Nimai Amin

+44 (0) 207 936 6453

Marketing

For media partnership enquiries please contact our publishing assistant: Sophie Hoare

Pharma Technology focus is powered by h5mag

read past issues of pharma technology focus HERE

Pharma Technology Focus is a product of Net Resources International. Copyright 2019 Net Resources International, a trading division of Kable Intelligence Limited. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.

Go to article: Home | Ingredients on demandGo to article: In this issueGo to article: Scandinavian HealthGo to article: ContentsGo to article: Daiichi JitsugyoGo to article: NewsGo to article: Hapa Company InsightGo to article: Gerteis Company InsightGo to article: GerteisGo to article: The pharma industry briefingGo to article: Accurate Biometrics Company InsightGo to article: Accurate BiometricsGo to article: Scott Gottlieb: achievements of the outgoing FDA commissionerGo to article: CapsugelGo to article: AlpexGo to article: Can Pharmaoffer become the Amazon of pharma raw materials?Go to article: Molnar Company InsightGo to article: MolnarGo to article: Is growth factor protein the future of Parkinson’s treatment?Go to article: AEB Company Insight Go to article: AEB Go to article: CBD: the myth, the magic and the real deal drugsGo to article: Swiss WorldCargoGo to article: Moehs Iberica SLGo to article: Could a pregnancy protein hold promise for new drugs?Go to article: AtoZ-CRO GmbH Company InsightGo to article: AtoZ-CRO GmbHGo to article: Antimicrobial resistance: sewage samples reveal bad sanitation as a key driverGo to article: BEAGo to article: 3MGo to article: PfanstiehlGo to article: EventsGo to article: Richter HelmGo to article: Event: CPhl KoreaGo to article: TSS Company InsightGo to article: TSS ABGo to article: Next issueGo to article: Baxter